Clinical guidelines for the management of children with lysosomal acid lipase deficiency

Lysosomal acid lipase deficiency is s a rare hereditary enzymopathy. The article presents epidemiological data and features of etiopathogenesis of two phenotypic forms of lysosomal acid lipase deficiency — Wolman disease and cholesterol ester storage disease. Special attention has been given to the key issues of differential diagnostic search, clinical guidelines based on the principles of evidence-based medicine have been given.

1. Valayannopoulos V, Mengel E, Brassier A, Grabowski G. Lysosomal acid lipase deficiency: Expanding differential diagnosis. Mol Genet Metab. 2017;120(1-2):62-66. doi: https://doi.org/10.1016/j.ymgme.2016.11.002

2. Bernstein DL, Hulkova H, Bialer MG, Desnick RJ. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013;58(6):1230-1243. doi: https://doi.org/10.1016/j.jhep.2013.02.014

3. Grabowski GA, Charnas L, Du H. Lysosomal acid lipase deficiencies: the Wolman disease/cholesteryl ester storage disease spectrum. In: Metabolic and molecular bases of inherited disease — OMMBID. Scriver Valle D, Beaudet AL, Vogelstein B, et al., eds. New York: McGraw-Hill; 2014.

4. Fouchier SW, Defesche JC. Lysosomal acid lipase A and the hyper-cholesterolaemic phenotype. Curr Opin Lipidol. 2013;24(4):332-338. doi: https://doi.org/10.1097/MOL.0b013e328361f6c6

5. Pericleous M, Kelly C, Wang T, et al. Wolman's disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency. Lancet Gastroenterol Hepatol. 2017;2(9):670-679. doi: https://doi.org/10.1016/S2468-1253(17)30052-3

6. Santos Silva E, Klaudel-Dreszler M, Bakula A, et al. Early onset lysosomal acid lipase deficiency presenting as secondary hemophagocytic lymphohistiocytosis: Two infants treated with sebelipase alfa. Clin Res Hepatol Gastroenterol. 2018;42(5):e77-e82. doi: https://doi.org/10.1016/j.clinre.2018.03.012

7. Sadhukhan M, Saha A, Vara R, Bhaduri B. Infant case of lysosomal acid lipase deficiency: Wolman's disease. BMJ Case Rep. 2014;2014:bcr2013202652. doi: https://doi.org/10.1136/bcr-2013-202652

8. Kamenets EA, Pechatnikova NL, Kakaulina VS, et al. Lysosome acid lipase deficiency in Russian patients: molecular characteristic and epydemiology. Medical Genetics. 2019;18(8):3-16. (In Russ). doi: https://doi.org/10.25557/2073-7998.2019.08.3-16

9. Witeck CDR, Schmitz AC, de Oliveira JMD, et al. Lysosomal acid lipase deficiency in pediatric patients: a scoping review. J Pediatr (Rio J). 2022;98(1):4-14. doi: https://doi.org/10.1016/j.jped.2021.03.003

10. Degtyareva AV, Puchkova AA, Zhdanova SI, Degtyarev DN. Wolman disease is a severe infant form of lysosomal acid lipase deficiency. Neonatologiya: novosti, mneniya, obuchenie = Neonatology: News, Opinions, Training. 2019;7(2):42-51. (In Russ). doi: https://doi.org/10.24411/2308-2402-2019-12003

11. Jones SA, Valayannopoulos V, Schneider E, et al. Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants. Genet Med. 2016;18(5):452-458. doi: https://doi.org/10.1038/gim.2015.108

12. Mayevskaya MV, Ivashkin VT, Zharkova MS, et al. Rare forms of nonalcoholic fatty liver disease: hereditary lysosomal acid lipase deficiency. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):41-51. (In Russ). doi: https://doi.org/10.22416/1382-4376-2016-26-3-41-51

13. Desai PK, Astrin KH, Thung SN, et al. Cholesteryl ester storage disease: pathologic changes in an affected fetus. Am J Med Genet. 1987;26(3):689-698. doi: https://doi.org/10.1002/ajmg.1320260324

14. Decarlis S, Agostoni C, Ferrante F, et al. Combined hyperlipidaemia as a presenting sign of cholesteryl ester storage disease. J Inherit Metab Dis. 2009;32 Suppl 1:S11-S13. doi: https://doi.org/10.1007/s10545-008-1027-2

15. Riva S, Spada M, Sciveres M, et al. Hepatocarcinoma in a child with cholesterol ester storage disease. Dig Liver Dis. 2008;40(9):784. doi: https://doi.org/10.1016/j.dld.2008.01.009

16. Hamilton J, Jones I, Srivastava R, Galloway P. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta. 2012;413(15-16):1207-1210. doi: https://doi.org/10.1016/j.cca.2012.03.019

17. Lukacs Z, Barr M, Hamilton J. Best practice in the measurement and interpretation of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta. 2017;471:201-205. doi: https://doi.org/10.1016/j.cca.2017.05.027

18. Hoffman EP, Barr ML, Giovanni MA, et al. Lysosomal Acid Lipase Deficiency. 2015 Jul 30 [Updated 2016 Sep 1]. In: GeneReviews® [Internet]. Adam MP, Ardinger HH, Pagon RA, et al., eds. Seattle (WA): University of Washington, Seattle; 1993-2020. Available online: https://www.ncbi.nlm.nih.gov/books/NBK305870. Accessed on July 13, 2023.

19. Quinn AG, Burton B, Deegan P, et al. Sustained elevations in LDL cholesterol and serum transaminases from early childhood are common in lysosomal acid lipase deficiency. Mol Genet Metab. 2014;111(2):S89. doi: https://doi.org/10.1016/j.ymgme.2013.12.215

20. Cohen JL, Burfield J, Valdez-Gonzalez K, et al. Early diagnosis of infantile-onset lysosomal acid lipase deficiency in the advent of available enzyme replacement therapy. Orphanet J Rare Dis. 2019;14(1):198. doi: https://doi.org/10.1186/s13023-019-1129-y

21. Al Essa M, Nounou R, Sakati N, et al. Wolman's disease: The King Faisal Specialist Hospital and Research Centre experience. Ann Saudi Med. 1998;18(2):120-124. doi: https://doi.org/10.5144/0256-4947.1998.120

22. Karpishchenko AI, Moskalev AV, Kuznetsov VV, Zheregelya SN. Klinicheskaya laboratornaya diagnostika zabolevanii pecheni i zhelchevyvodyashchikh putei: Guide for doctors. Karpishchenko AI, ed. Moscow: GEOTAR-Media; 2020. 464 p. (In Russ). doi: https://doi.org/10.33029/9704-5256-1-LIV-2020-1-464

23. Tolar J, Petryk A, Khan K, et al. Long-term metabolic, endocrine, and neuropsychological outcome of hematopoietic cell transplantation for Wolman disease. Bone Marrow Transplant. 2009;43(1):21-27. doi: https://doi.org/10.1038/bmt.2008.273

24. Kohli R, Ratziu V, Fiel MI, et al. Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group. Mol Genet Metab. 2020;129(2):59-66. doi: https://doi.org/10.1016/j.ymgme.2019.11.004

25. Hulkova H, Elleder M. Distinctive histopathological features that support a diagnosis of cholesterol ester storage disease in liver biopsy specimens. Histopathology. 2012;60(7):1107-1113. doi: https://doi.org/10.1111/j.1365-2559.2011.04164.x

26. Harrison SA. Management of Lysosomal Acid Lipase Deficiency for the Gastroenterologist and Hepatologist. Gastroenterol Hepatol (N Y). 2016;12(5):331-333.

27. Jones SA, Rojas-Caro S, Quinn AG, et al. Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study. Orphanet J Rare Dis. 2017;12(1):25. doi: https://doi.org/10.1186/s13023-017-0587-3

28. Burton BK, Balwani M, Feillet F, et al. A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N Engl J Med. 2015;373(11):1010-1020. doi: https://doi.org/10.1056/NEJMoa1501365

29. Abel F, Arnoux JB, Kostyleva M, et al. Benefit of Sebelipase Alfa in Children and Adults With Lysosomal Acid Lipase Deficiency Based on Analysis of Efficacy Overall and by Baseline Alanine Aminotransferase Level. J Hepatol. 2016;64(2):298-299. doi: https://doi.org/10.1016/S0168-8278(16)00382-2

30. Su K, Donaldson E, Sharma R. Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa. Appl Clin Genet. 2016;9:157-167. doi: https://doi.org/10.2147/TACG.S86760

31. Valayannopoulos V, Malinova V, Honz^k T, et al. Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. J Hepatol. 2014;61(5):1135-1142. doi: https://doi.org/10.1016/j.jhep.2014.06.022

32. Maciejko JJ. Managing Cardiovascular Risk in Lysosomal Acid Lipase Deficiency. Am J Cardiovasc Drugs. 2017;17(3):217-231. doi: https://doi.org/10.1007/s40256-017-0216-5

33. Strebinger G, Muller E, Feldman A, Aigner E. Lysosomal acid lipase deficiency — early diagnosis is the key. Hepat Med. 2019;11:79-88. doi: https://doi.org/10.2147/HMER.S201630

34. Dixon DB. Non-Invasive Techniques in Pediatric Dyslipidemia. In: Endotext. Feingold KR, Anawalt B, Boyce A, et al., eds. South Dartmouth (MA): MDText.com, Inc.; 2020.

35. Zharkova M, Nekrasova T, Ivashkin V, et al. Fatty Liver and Systemic Atherosclerosis in a Young, Lean Patient: Rule Out Lysosomal Acid Lipase Deficiency. Case Rep Gastroenterol. 2019;13(3):498-507. doi: https://doi.org/10.1159/000504646

36. Erwin AL. The role of sebelipase alfa in the treatment of lysosomal acid lipase deficiency. Therap Adv Gastroenterol. 2017;10(7):553-562. doi: https://doi.org/10.1177/1756283X17705775

37. Venoznyi dostup: Guidelines. Ministry of Health of Russian Federation; 2019. 82 p. (In Russ). Доступно по: https://msestra.ru/download/file.php?id=4763. Ссылка активна на 18.07.2023.

38. Sebelipase alfa. Registration certificate No. ЛП-004513. Registration date: Ocrober 31, 2017. In: State Register of Medicines: official website. (In Russ). Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1eaa9c5e-20c6-4a75-a48c-44f5271fcf4d. Ссылка активна на 14.07.2023.

39. Jones SA, AlSayed M, Broomfield AA, et al. Management guidelines for infantile onset lysosomal acid lipase deficiency (LALD). Mol Genet Metab. 2018;123(2):S72-S73. doi: https://doi.org/10.1016/j.ymgme.2017.12.180

40. Malinova V, Balwani M, Sharma R, et al. Sebelipase alfa for lysosomal acid lipase deficiency: 5-year treatment experience from a phase 2 open-label extension study. Liver Int. 2020;40(9):2203-2214. doi: https://doi.org/10.1111/liv.14603

41. Attachment 2 KANUMA — Sebelipase — Alexion Pharmaceuticals Australia Pty Ltd — PM-2016-01313-1-3 — Extract from the CER FINAL 14 June 2018. Available online: https://www.tga.gov.au/sites/default/files/auspar-sebelipase-alfa-180614-cer.pdf. Accessed on July 13, 2023.

42. Pastores GM, Hughes DA. Lysosomal Acid Lipase Deficiency: Therapeutic Options. Drug Des Devel Ther. 2020;14:591-601. doi: https://doi.org/10.2147/DDDT.S149264

43. Gramatges MM, Dvorak CC, Regula DP, et al. Pathological evidence of Wolman's disease following hematopoietic stem cell transplantation despite correction of lysosomal acid lipase activity. Bone Marrow Transplant. 2009;44(7):449-450. doi: https://doi.org/10.1038/bmt.2009.57

44. Stein J, Garty BZ, Dror Y, et al. Successful treatment of Wolman disease by unrelated umbilical cord blood transplantation. Eur J Pediatr. 2007;166(7):663-666. doi: https://doi.org/10.1007/s00431-006-0298-6

45. Yanir A, Allatif MA, Weintraub M, Stepensky P. Unfavorable outcome of hematopoietic stem cell transplantation in two siblings with Wolman disease due to graft failure and hepatic complications. Mol Genet Metab. 2013;109(2):224-226. doi: https://doi.org/10.1016/j.ymgme.2013.03.007

46. Lobanova EV, Lavrova AE, Konovalova EYu, et al. Deficiency of lysosomal acid lipase in a 5 years old child. Pediatria. Journal n.a. G.N. Speransky. 2017;96(6):183-186. (In Russ).

47. Kale AS, Ferry GD, Hawkins EP. End-stage renal disease in a patient with cholesteryl ester storage disease following successful liver transplantation and cyclosporine immunosuppression. J Pediatr Gastroenterol Nutr. 1995;20(1):95-97. doi: https://doi.org/10.1097/00005176-199501000-00016

48. Ambler GK, Hoare M, Brais R, et al. Orthotopic liver transplantation in an adult with cholesterol ester storage disease. JIMD Rep. 2013;8:41-46. doi: https://doi.org/10.1007/8904_2012_155

49. Bernstein DL, Lobritto S, Iuga A, et al. Lysosomal acid lipase deficiency allograft recurrence and liver failure- clinical outcomes of 18 liver transplantation patients. Mol Genet Metab. 2018;124(1):11-19. doi: https://doi.org/10.1016/j.ymgme.2018.03.010